scholarly journals Long Term Experience in Patients With JIA-Associated Uveitis in a Large Referral Center

2021 ◽  
Vol 9 ◽  
Author(s):  
Luca Marelli ◽  
Micol Romano ◽  
Irene Pontikaki ◽  
Maurizio Virgilio Gattinara ◽  
Paolo Nucci ◽  
...  
Keyword(s):  
Adverse Events ◽  
Treatment Approach ◽  
Age At Onset ◽  
Laboratory Data ◽  
Local Therapy ◽  
Ocular Complications ◽  
Good Safety Profile ◽  
Band Keratopathy ◽  
Long Term Experience

Objectives: To describe demographic, clinical and therapeutic findings of a large cohort of patients with JIA-associated uveitis in a nationwide referral pediatric rheumatology and uveitis center in Northern Italy.Methods: Retrospective study of 125 patients with JIA-associated uveitis followed from 2009 to 2019. Demographic and rheumatologic features including JIA ILAR classification, age at onset, and laboratory data were recorded. Ocular findings collected were: anatomic location of uveitis, laterality, type, recurrence rate, visual acuity, ocular complications, and local therapy. Systemic therapy with conventional and biologic immunosuppressants, occurrence of adverse events, and duration of treatments were recorded.Results: One hundred and twenty-five patients with JIA-associated uveitis were followed for a meantime of 9.2 (±1.7) years. Oligoarticular JIA was present in 92.8% of patients and anterior uveitis in 96%. The most common ocular complications recorded in our sample were posterior synechiae (37.6%), cataract (20.8%), band keratopathy (19.2%), glaucoma (7.2%), and macular edema (5.6%). Conventional immunosuppressants were used in 75.2% of patients with a mean duration of 9.1 years (±5.4), while biologics were administered in 47.2% of them for a period of 5.4 years. Adverse events (AE) were seen in 23% of patients being treated with Methotrexate, in 10.4% of patients treated with Adalimumab, in 38.5% of patients in therapy with Infliximab, and in 14.3% of patients being treated with Tocilizumab. No AE were reported in patients treated with Golimumab, Certolizumab, Abatacept and Rituximab.Conclusions: An aggressive treatment approach for patients with JIA-associated uveitis ensured a low number of ocular complications with a good safety profile.

Long-term oxygen therapy in children with sickle cell disease and hypoxaemia

2020 ◽  
pp. archdischild-2020-319347
Author(s):  
Ilaria Liguoro ◽  
Michele Arigliani ◽  
Bethany Singh ◽  
David Rees ◽  
Baba P D Inusa ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Adverse Events ◽  
Sickle Cell ◽  
Oxygen Therapy ◽  
Laboratory Data ◽  
Cell Disease ◽  
Overnight Oximetry ◽  
Long Term Oxygen Therapy ◽  
Major Adverse Events

ObjectiveTo evaluate the acceptability and safety profile of nocturnal long-term oxygen therapy (LTOT) in children with sickle cell disease (SCD) and chronic hypoxaemia.DesignRetrospective cohort study.Patients, setting and interventionChildren with SCD who started LTOT from 2014 to early 2019 in two tertiary hospitals in London, UK were retrospectively enrolled. Patients who started disease-modifying therapies <12 months before LTOT or while on LTOT were excluded.Main outcome measuresMinor and major adverse events during LTOT were reported. Laboratory and clinical data, transcranial Doppler (TCD) scans and overnight oximetry studies performed at steady state within 12 months before and after starting LTOT were compared.ResultsNineteen children (10 males; median age 12 years, range 6–15) were included. Nearly half of them (9/19; 47%) were on hydroxyurea at baseline. No child discontinued LTOT because of intolerance or poor adherence. No major adverse events were reported. Laboratory data did not show significant changes in haemoglobin and reticulocyte count after 1 year of follow-up. No statistically significant change in the incidence of vaso-occlusive pain events was noted (median annual rate from 0.5 to 0 episode per patient/year; p=0.062). Overnight oximetry tests performed while on LTOT showed improvements in all oxygen saturation parameters (mean overnight and nadir SpO2, % of time spent with SpO2 <90%) compared with the baseline.ConclusionLTOT is a safe and feasible treatment option for children with SCD and chronic hypoxaemia.

scholarly journals 1016 LOW RATES OF NUCLEOS(T)IDE-ASSOCIATED ADVERSE EVENTS IN THE LONG-TERM EXPERIENCE WITH ENTECAVIR

2010 ◽  
Vol 52 ◽  
pp. S393 ◽  
Author(s):  
M. Manns ◽  
U.S. Akarca ◽  
T.-T. Chang ◽  
W. Sievert ◽  
S.-K. Yoon ◽  
...  
Keyword(s):  
Adverse Events ◽  
Long Term Experience

Remission Rates of Children and Adolescents with Thyrotoxicosis Treated with Antithyroid Drugs

PEDIATRICS ◽  
1980 ◽  
Vol 65 (3) ◽  
pp. 550-556
Author(s):  
Roberta J. Collen ◽  
Elliot M. Landaw ◽  
Solomon A. Kaplan ◽  
Barbara M. Lippe
Keyword(s):  
Medical Therapy ◽  
Remission Rate ◽  
Age At Onset ◽  
Laboratory Data ◽  
Antithyroid Drugs ◽  
Sustained Remission ◽  
Table Analysis ◽  
One Year

The clinical course of 65 children with hyperthyrodism in whom antithyroid medication was initiated has been reviewed retrospectively. Fifty-five patients received only this projected medical therapy with propylthiouracil or methimazole. Sustained remission in excess of one year following cessation of drugs occurred in 31 patients (56%). All but two achieved that remission within 4.5 years. Of the 31 patients, 24 have been followed-up for more than two years off medication with only one relapse. Twenty-four patients are still under medical therapy, 14 for longer than 4.5 years. By methods of life-table analysis, the data on all 65 patients gave an estimate of 25% remitting within the first two years and a median remission time of 4 to 4.5 years. These results suggest a continuing remission rate of 25% every two years for up to six years of follow-up. Analysis of presenting variables (assessment of age at onset of disease, sex, family history, initial laboratory data, gland size, and degree of exophthalmos) that might have distinguished which patients were likely to undergo remission was attempted. There were no clearly significant differences with any of these variables although several suggestive differences emerged. These included a tendency toward earlier remission in patients older than 13 years, in boys of any age, and in patients of any age or sex in whom initial triiodothyronine (T3 RIA) &lt; was 645 ng/100 ml. An approach to long-term medical management is proposed.

M1901 Low Rates of Nucleos(T)Ide-Associated Adverse Events in the Long-Term Experience With Entecavir

2010 ◽  
Vol 138 (5) ◽  
pp. S-832
Author(s):  
Albert D. Min ◽  
Naoky Tsai ◽  
Michael P. Manns ◽  
Ulus S. Akarca ◽  
Ting-Tsung Chang ◽  
...  
Keyword(s):  
Adverse Events ◽  
Long Term Experience

Long Term Experience with Seawalls on an Exposed Coast

1989 ◽  
Author(s):  
Orville T. Magoon ◽  
Joan L. Pope ◽  
Robert L. Sloan ◽  
Donald D. Treadwell
Keyword(s):  
Long Term Experience

Modern prevention and active longevity programs on the basis of disruptive domestic technologies: positive experience and prospects for application

2020 ◽  
pp. 66-73
Author(s):  
A. Simonova ◽  
S. Chudakov ◽  
R. Gorenkov ◽  
V. Egorov ◽  
A. Gostry ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Early Detection ◽  
Laboratory Diagnostics ◽  
Positive Experience ◽  
Practical Application ◽  
Wide Range ◽  
Integrated Program ◽  
Long Term Experience ◽  
Early Detection And Prevention

The article summarizes the long-term experience of practical application of domestic breakthrough technologies of preventive personalized medicine for laboratory diagnostics of a wide range of socially significant non-infectious diseases. Conceptual approaches to the formation of an integrated program for early detection and prevention of civilization diseases based on these technologies are given. A vision of the prospects for the development of this area in domestic and foreign medicine has been formed.

Sign in / Sign up

Export Citation Format

Share Document